TY - JOUR
T1 - Emerging therapeutic developments in neurodegenerative diseases
T2 - A clinical investigation
AU - Kumar, Dhiraj
AU - Md Ashraf, Ghulam
AU - Bilgrami, Anwar L.
AU - Imtaiyaz Hassan, Md
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/10
Y1 - 2022/10
N2 - Despite a century of intensive research, there is still a lack of disease-modifying treatments for neurodegenerative diseases that pose a threat to human society. A well-documented knowledge and resource gap has impeded the translation of fundamental research into promising therapies. In addition, the analysis of extensive preclinical data to allow the improved selection of therapeutic technologies and clinical candidates for further development is challenging. To address this need, we describe technologies that have emerged over the past decade that have enabled the development of novel, high-quality, cost-effective treatments for major neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Moreover, we benchmark emerging technologies that have been adopted by top pharmaceutical companies looking to bridge the gap between drug discovery and drug development in neurodegenerative disease.
AB - Despite a century of intensive research, there is still a lack of disease-modifying treatments for neurodegenerative diseases that pose a threat to human society. A well-documented knowledge and resource gap has impeded the translation of fundamental research into promising therapies. In addition, the analysis of extensive preclinical data to allow the improved selection of therapeutic technologies and clinical candidates for further development is challenging. To address this need, we describe technologies that have emerged over the past decade that have enabled the development of novel, high-quality, cost-effective treatments for major neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Moreover, we benchmark emerging technologies that have been adopted by top pharmaceutical companies looking to bridge the gap between drug discovery and drug development in neurodegenerative disease.
KW - Clinical products
KW - Drug discovery
KW - Emerging technologies
KW - Neurodegenerative disease
KW - Pharmaceutical development
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85133374993&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2022.06.005
DO - 10.1016/j.drudis.2022.06.005
M3 - Review article
C2 - 35728774
AN - SCOPUS:85133374993
SN - 1359-6446
VL - 27
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 10
M1 - 103305
ER -